Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 8/20 | 0.93 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 8/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THRB | P10828 | 2/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 2/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.93 |
| ▸ | DRD3 | P35462 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen SCHEMBL2996117 | 1.00 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 0.96 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 0.96 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL351220 | 0.96 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 0.96 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL1417519 | 0.95 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.95 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL656539 | 0.95 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.93 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL22352888 | 0.90 | GABBR2 (0.87) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236445-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF ALZHEIMER'S DISEASE IN PATIENTS HAVING LOST RESPONSIVENESS TO ACETYLCHOLINESTERASE INHIBITOR THERAPY | PHARNEXT (FR) | 2021-08-05 | — | — | US | disclosed |
| EP-3443955-B1 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-20210069135-A1 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS | PHARNEXT (FR) | 2021-03-11 | — | — | US | disclosed |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | PHARNEXT (FR) | 2021-02-02 | — | — | US | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| EP-2892520-B1 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS | PHARNEXT (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3348261-B1 | NEW COMPOSITIONS COMPRISING BACLOFEN, ACAMPROSATE AND RILUZOLE | PHARNEXT (FR) | 2020-10-21 | — | — | EP | disclosed |
| US-10799499-B2 | Combinatorial therapies of neurological disorders | PHARNEXT (FR) | 2020-10-13 | — | — | US | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-10736876-B2 | Idalopirdine-based combinatorial therapies of Alzheimer's disease | PHARNEXT (FR) | 2020-08-11 | — | — | US | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012117075-A2 | TREATMENT OF CEREBRAL ISCHEMIA | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012117073-A2 | NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| US-20100197789-A1 | ANTI-OBESITY AGENT AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| CN-101500610-A | Anti-obesity agent and use thereof | UNIV NAGOYA NAT UNIV CORP (JP) | 2009-08-05 | — | — | CN | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| EP-2058008-A1 | ANTI-OBESITY AGENT AND USE THEREOF | National University Corporation Nagoya University (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | CPT1B, APOB, GABRB3 | GABBR2 13/4885GABBR1 12/4885LMNA 3223/4885 |
| US-20100197789-A1 | ANTI-OBESITY AGENT AND USE THEREOF | GPR119, GABRB2, GABRB3 | GABBR2 16/4885GABBR1 17/4885LMNA 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.